Ovary Removal Before Menopause Linked to Cognitive Impairment, Dementia Risk

Translate to Spanish or other 102 languages!

A new study shows that ovary removal before menopause is linked to decreased white matter in the brain later in life. Image for illustration purposes
A new study shows that ovary removal before menopause is linked to decreased white matter in the brain later in life. Image for illustration purposes
- Advertisement -
  • A new study examined the brains of females who underwent full ovary removal before going through menopause.
  • Sometimes, females must undergo this type of procedure to treat conditions such as ovarian cancer or endometriosis.
  • The study’s findings show that females who undergo ovary removal before menopause have a decrease in white matter in their brains later in life. 
  • A decrease in white matter is linked to cognitive impairment.

A new study examined the cognitive effects of ovary removal in females.

Follow the link below to Medical News Today to read the full story:

https://www.medicalnewstoday.com/articles/ovary-removal-before-menopause-cognitive-decline-dementia-risk?slot_pos=article_2&utm_source=Sailthru%20Email&utm_medium=Email&utm_campaign=MNT%20Daily%20News&utm_content=2024-06-28&apid=&rvid=4ba4ec80177cae00eabc43b8bc6648d598c4a356d104663735777e0a0f8b5c9f

- Advertisement -

Information Source: https://www.medicalnewstoday.com

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

Study: Supplement Plus Chemo Boosts Pancreatic Cancer Survival

L-glutamine, an amino acid that occurs naturally in the body and plays an important role in digestion, has been studied as a potential way to ease side effects in other cancers.

How Artificial Intelligence Is Improving Prostate Cancer Diagnostics

Mega Doctor News CLEVELAND CLINIC - September is Prostate Cancer Awareness Month.  Prostate cancer is...

New Strategies to Soothe Dry Eyes

Anyone who has ever endured burning, itchy eyes or extra tearing knows that these symptoms are tough to ignore.

FDA Approves First Drug of Its Kind for Polycythemia Vera, a Rare Blood Disorder

The U.S. Food and Drug Administration today approved Mimrylo (rusfertide), a new treatment for adults with polycythemia vera, a rare blood disorder that causes the body to make too many red blood cells.
- Advertisement -